title: Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide.
abstract: Genetic, neuropathological, and biochemical studies have provided strong evidence for a central role of amyloid in the pathogenesis of Alzheimer's disease (AD). We have proposed previously that peptides designed as beta-sheet breakers may be useful in preventing the formation of amyloid plaques. In this study, we describe a modified beta-sheet breaker peptide with improved pharmacological properties, a high rate of penetration across the blood-brain barrier, and the ability to induce a dramatic reduction in amyloid deposition in two different transgenic AD models. In addition, we report for the first time a significant increase in neuronal survival and a decrease in brain inflammation associated with the reduction of amyloid plaques. These results demonstrate that the process of amyloid deposition is one of the causes of neurodegeneration in AD. Moreover, our findings indicate that beta-sheet breaker peptides provide a valuable tool for evaluating further the importance of amyloid in the etiology of AD and suggest that these peptides or some of their derivatives might be good candidates for AD treatment.
authors.affiliation: Serono Pharmaceutical Research Institute, 1228 Geneva, Switzerland.
authors.forename: Bruno
authors.initials: B
authors.lastname: Permanne
authors.forename: Céline
authors.initials: C
authors.lastname: Adessi
authors.forename: Gabriela P
authors.initials: GP
authors.lastname: Saborio
authors.forename: Santiago
authors.initials: S
authors.lastname: Fraga
authors.forename: Marie-José
authors.initials: MJ
authors.lastname: Frossard
authors.forename: Jo
authors.initials: J
authors.lastname: Van Dorpe
authors.forename: Ilse
authors.initials: I
authors.lastname: Dewachter
authors.forename: William A
authors.initials: WA
authors.lastname: Banks
authors.forename: Fred
authors.initials: F
authors.lastname: Van Leuven
authors.forename: Claudio
authors.initials: C
authors.lastname: Soto
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000682:Amyloid / Q000187:drug effects* / Q000378:metabolism; D016564:Amyloid beta-Protein Precursor / Q000235:genetics; D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects; D001921:Brain / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology; D016923:Cell Death / Q000187:drug effects; D004195:Disease Models, Animal; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D053764:Presenilin-1
chemical_list: D000682:Amyloid; D016564:Amyloid beta-Protein Precursor; D008565:Membrane Proteins; C508853:PSEN1 protein, human; D010446:Peptide Fragments; D053764:Presenilin-1